Charlotte-Paige Rolle, MD
Director of Research Operations
- Massachusetts Medical Society
- Infectious Disease Society of America
- HIV Specialist through the American Academy of HIV Medicine
- Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic.
- Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
- Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
- Risk of COVID-19 after natural infection or vaccination.
- Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
- Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
- Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
- From declining PrEP to PrEP initiation as “first nature” – what changes PrEP initiation decisions among young, Black MSM.
- Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
- Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
- Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting.
- Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida.
- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
- PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA.
- Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM.
- Use of a Prospective Sex Diary to Study Anal Lubricant and Enema Use Among High Risk Men Who Have Sex With Men-Implications for Human Immunodeficiency Virus Prevention.
- Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia.
- Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic.
- Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
- Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
- Risk of COVID-19 after natural infection or vaccination.
- Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
- Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
- Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
- From declining PrEP to PrEP initiation as “first nature” – what changes PrEP initiation decisions among young, Black MSM.
- Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
- Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
- Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting.
- Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida.
- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
- PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA.
- Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM.
- Use of a Prospective Sex Diary to Study Anal Lubricant and Enema Use Among High Risk Men Who Have Sex With Men-Implications for Human Immunodeficiency Virus Prevention.
- Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia.
- Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic.
- Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
- Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
- Risk of COVID-19 after natural infection or vaccination.
- Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
- Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
- Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV.
- From declining PrEP to PrEP initiation as “first nature” – what changes PrEP initiation decisions among young, Black MSM.
- Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
- Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
- Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting.
- Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida.
- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
- PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA.
- Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM.
- Use of a Prospective Sex Diary to Study Anal Lubricant and Enema Use Among High Risk Men Who Have Sex With Men-Implications for Human Immunodeficiency Virus Prevention.
- Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia.
Dr. Rolle is the Director of Research Operations at Orlando Immunology Center. She is a graduate of the University of Chicago Pritzker School of Medicine and obtained a Master’s in Public Health at the Harvard School of Medicine. She completed a Fellowship at Emory University in Atlanta and has conducted research in various areas from HIV testing laws to PrEP, publishing many papers. She is certified as an HIV Specialist through the American Academy of HIV Medicine (AAHIVM).
Dr. Rolle’s passion for helping those with HIV began in high school when she volunteered at a homeless shelter for people living with HIV. She continued her advocacy in college and developed HIV and STI education and prevention programs for youth and women.
She has treated patients in Chicago, Atlanta, Boston, Haiti, and Rwanda giving her a global perspective on HIV treatment and care. We are thrilled that Dr. Rolle will bring this wealth of research and patient care experience to Central Florida and will ensure that OIC remains the at the forefront for the prevention, evaluation and treatment of all STIs and Hepatitis in Central Florida.